HK1159249A1 - Kit for the identification of ovarian cancer protein biomarkers using proteomic techniques - Google Patents

Kit for the identification of ovarian cancer protein biomarkers using proteomic techniques

Info

Publication number
HK1159249A1
HK1159249A1 HK11113784.0A HK11113784A HK1159249A1 HK 1159249 A1 HK1159249 A1 HK 1159249A1 HK 11113784 A HK11113784 A HK 11113784A HK 1159249 A1 HK1159249 A1 HK 1159249A1
Authority
HK
Hong Kong
Prior art keywords
identification
ovarian cancer
kit
biomarkers
cancer
Prior art date
Application number
HK11113784.0A
Other languages
English (en)
Inventor
Gil G Mor
David C Ward
Patricia Bray-Ward
Original Assignee
Univ Yale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Yale filed Critical Univ Yale
Publication of HK1159249A1 publication Critical patent/HK1159249A1/xx

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16Z—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS, NOT OTHERWISE PROVIDED FOR
    • G16Z99/00—Subject matter not provided for in other main groups of this subclass
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/5756—Prolactin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/65—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/99—Isomerases (5.)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
HK11113784.0A 2004-02-19 2011-12-21 Kit for the identification of ovarian cancer protein biomarkers using proteomic techniques HK1159249A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54558104P 2004-02-19 2004-02-19
US54590004P 2004-02-20 2004-02-20

Publications (1)

Publication Number Publication Date
HK1159249A1 true HK1159249A1 (en) 2012-07-27

Family

ID=34915557

Family Applications (2)

Application Number Title Priority Date Filing Date
HK09107579.5A HK1129729A1 (en) 2004-02-19 2009-08-18 Identification of cancer protein biomarkers using proteomic techniques
HK11113784.0A HK1159249A1 (en) 2004-02-19 2011-12-21 Kit for the identification of ovarian cancer protein biomarkers using proteomic techniques

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK09107579.5A HK1129729A1 (en) 2004-02-19 2009-08-18 Identification of cancer protein biomarkers using proteomic techniques

Country Status (9)

Country Link
US (4) US7666583B2 (xx)
EP (3) EP2336779B1 (xx)
JP (3) JP4912894B2 (xx)
CN (1) CN1922490B (xx)
AU (1) AU2005217375C1 (xx)
CA (1) CA2557438C (xx)
HK (2) HK1129729A1 (xx)
IL (1) IL177591A (xx)
WO (1) WO2005083440A2 (xx)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7270960B2 (en) 2001-08-29 2007-09-18 Pacific Northwest Research Institute Diagnosis of ovarian carcinomas
CA2535805A1 (en) * 2003-08-15 2005-02-24 University Of Pittsburgh Of The Commnonwealth System Of Higher Education Multifactorial assay for cancer detection
US20070042405A1 (en) * 2003-08-15 2007-02-22 University Of Pittsburgh -Of The Commonwealth System Of Higher Education Enhanced diagnostic multimarker serological profiling
US20050277137A1 (en) * 2003-08-15 2005-12-15 University Of Pittsburgh Diagnostic multimarker serological profiling
EP2336779B1 (en) * 2004-02-19 2013-07-31 Yale University Kit for the identification of ovarian cancer protein biomarkers using proteomic techniques
US20080050832A1 (en) * 2004-12-23 2008-02-28 Buechler Kenneth F Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
US7910318B2 (en) 2005-09-15 2011-03-22 The Royal Institution For The Advancement Of Learning/Mcgill University Methods of diagnosing ovarian cancer and kits therefor
JP2009510478A (ja) * 2005-10-03 2009-03-12 バイオサイト インコーポレイテッド 全身性炎症反応症候群の診断および／または予後診断のための方法および組成物
CA2629013A1 (en) * 2005-11-10 2007-12-13 Aurelium Biopharma Inc. Method of diagnosing breast cancer using protein markers
CN101346628A (zh) * 2005-12-22 2009-01-14 霍夫曼-拉罗奇有限公司 包含骨桥蛋白和癌胚抗原的标记物组合在结肠直肠癌的评估中的用途
CA2949753A1 (en) * 2005-12-22 2007-07-05 Abbott Molecular Inc. Methods and marker combinations for screening for predisposition to lung cancer
EP3026119B1 (en) * 2006-01-04 2019-09-18 Fujirebio America, Inc. Use of he4 and other biochemical markers for assessment of ovarian cancers
EP1806587A1 (en) * 2006-01-07 2007-07-11 Université de Liège An in-vitro method for screening accessible biological markers in pathologic tissues
WO2008018905A2 (en) * 2006-01-17 2008-02-14 Cellumen, Inc. Method for predicting biological systems responses
EP2363711A1 (en) * 2006-01-27 2011-09-07 Tripath Imaging, Inc. Methods for identifying patients with an increased likelihood of having ovarian cancer and compositions therefor
EP1994410B1 (en) * 2006-01-31 2010-10-27 Medical Research Fund of Tel Aviv Sourasky Medical Center Methods for early detection of cancer
NZ545243A (en) * 2006-02-10 2009-07-31 Pacific Edge Biotechnology Ltd Urine gene expression ratios for detection of cancer
JP5406019B2 (ja) 2006-05-17 2014-02-05 セルーメン、インコーポレイテッド 自動化組織分析のための方法
AU2007262635B2 (en) 2006-06-23 2014-09-11 Adc Therapeutics Sa Polynucleotides and polypeptide sequences involved in cancer
CA2663595A1 (en) * 2006-08-07 2008-02-14 The Board Of Regents Of The University Of Texas System Proteomic patterns of cancer prognostic and predictive signatures
US20100112602A1 (en) * 2006-11-10 2010-05-06 Taylor Lansing D Protein-Protein Interaction Biosensors and Methods of Use Thereof
US20090047694A1 (en) * 2007-08-17 2009-02-19 Shuber Anthony P Clinical Intervention Directed Diagnostic Methods
US8221995B2 (en) * 2007-03-23 2012-07-17 Seok-Won Lee Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
US20090004755A1 (en) * 2007-03-23 2009-01-01 Biosite, Incorporated Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
WO2008118798A1 (en) * 2007-03-23 2008-10-02 University Of Pittsburgh Of The Commonwealth System Of Higher Education Multimarker assay for early detection of ovarian cancer
US8455189B2 (en) * 2007-03-29 2013-06-04 Jeffrey W. Allard Use of HE4 for assessment of breast cancers
US20090029372A1 (en) * 2007-05-14 2009-01-29 Kobenhavns Universitet Adam12 as a biomarker for bladder cancer
CN101855553B (zh) 2007-06-29 2014-06-11 韩国安国药品株式会社 卵巢癌的预测标记
FR2919063B1 (fr) * 2007-07-19 2009-10-02 Biomerieux Sa Procede de dosage du leucocyte elastase inhibitor pour le diagnostic in vitro du cancer colorectal.
FR2919064B1 (fr) * 2007-07-19 2009-10-02 Biomerieux Sa Procede de dosage de l'apolipoproteine all pour le diagnostic in vitro du cancer colorectal
FR2919061B1 (fr) * 2007-07-19 2009-10-02 Biomerieux Sa Procede de dosage de la plastine-i pour le diagnostic in vitro du cancer colorectal.
FR2919065B1 (fr) * 2007-07-19 2009-10-02 Biomerieux Sa Procede de dosage de l'apolipoproteine ai pour le diagnostic in vitro du cancer colorectal
CA2693098C (fr) * 2007-07-19 2019-06-18 Yasemin Ataman-Onal Procede de dosage de la proteine de liaison hepatique aux acides gras, de l'antigene carcino-embryonnaire, et de l'antigene carbohydrate 19-9 pour le diagnostic in vitro du cancercolorectal
FR2919062B1 (fr) * 2007-07-19 2009-10-02 Biomerieux Sa Procede de dosage de l'aminoacylase 1 pour le diagnostic in vitro du cancer colorectal.
FR2919060B1 (fr) * 2007-07-19 2012-11-30 Biomerieux Sa Procede de dosage de l'ezrine pour le diagnostic in vitro du cancer colorectal.
US20090075266A1 (en) * 2007-09-14 2009-03-19 Predictive Biosciences Corporation Multiple analyte diagnostic readout
WO2009024528A1 (en) * 2007-08-17 2009-02-26 Novartis Ag Use of cyclic depsipeptides to inhibit kallikrein 7
US8431367B2 (en) 2007-09-14 2013-04-30 Predictive Biosciences Corporation Detection of nucleic acids and proteins
US20100267041A1 (en) * 2007-09-14 2010-10-21 Predictive Biosciences, Inc. Serial analysis of biomarkers for disease diagnosis
US7955822B2 (en) * 2007-09-14 2011-06-07 Predictive Biosciences Corp. Detection of nucleic acids and proteins
WO2009039190A1 (en) * 2007-09-17 2009-03-26 Gene Express, Inc. Cancer risk biomarker
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
FI20070820A0 (fi) * 2007-10-30 2007-10-30 Faron Ventures Oy Menetelmä angiogeneesin estoon tai syövän hoitoon
US8357501B2 (en) * 2007-11-29 2013-01-22 Molecular Health Gmbh Tissue protective erythropoietin receptor (NEPOR) and methods of use
EP2088204A1 (en) * 2008-02-05 2009-08-12 Adnagen AG Method and kit for diagnosing or controlling the treatment of ovarian cancer
EP2279417B1 (en) * 2008-05-28 2016-07-20 Georgia Tech Research Corporation Metabolic biomarkers for ovarian cancer and methods of use thereof
WO2010005521A1 (en) * 2008-06-30 2010-01-14 Bltn, Llc Azelaic acid ester compositions and methods for diagnosing and treating tissue conditions using azelaic acid ester compositions and proteinaceous biomarkers
FR2933773B1 (fr) 2008-07-10 2013-02-15 Biomerieux Sa Procede de dosage de la proteine disulfide isomerase pour le diagnostic in vitro du cancer colorectal
WO2010022227A1 (en) * 2008-08-20 2010-02-25 Schering Corporation Methods for monitoring il-10 therapy
US10359425B2 (en) 2008-09-09 2019-07-23 Somalogic, Inc. Lung cancer biomarkers and uses thereof
US20100221752A2 (en) * 2008-10-06 2010-09-02 Somalogic, Inc. Ovarian Cancer Biomarkers and Uses Thereof
CN104829714A (zh) 2008-11-03 2015-08-12 阿莱斯亚生物疗法股份有限公司 特异性地阻滞肿瘤抗原的生物活性的抗体
KR100980031B1 (ko) * 2009-06-17 2010-09-06 주식회사 바이오인프라 대장암 진단 및 스크리닝용 단백질 마커 및 대장암 진단을 위한 상기 마커의 측정방법
WO2011083391A2 (en) * 2010-01-05 2011-07-14 Pfizer Inc. Biomarkers for anti-igf-ir cancer therapy
KR20130056855A (ko) * 2010-03-01 2013-05-30 카리스 라이프 사이언스 룩셈부르크 홀딩스 치료진단용 생물학적 지표들
SG10201508656VA (en) 2010-07-09 2015-11-27 Somalogic Inc Lung cancer biomarkers and uses thereof
US20120171694A1 (en) * 2010-07-30 2012-07-05 Vermillion, Inc. Predictive markers and biomarker panels for ovarian cancer
US20120040861A1 (en) 2010-08-13 2012-02-16 Somalogic, Inc. Pancreatic Cancer Biomarkers and Uses Thereof
MY166040A (en) 2010-09-15 2018-05-21 Almac Diagnostics Ltd Molecular diagnostic test for cancer
CA2818976A1 (en) * 2010-11-26 2012-05-31 Oncolab Diagnostics Gmbh Multimarker panel
AU2012220896B2 (en) * 2011-02-24 2016-11-24 Aspira Women’s Health Inc. Biomarker panels, diagnostic methods and test kits for ovarian cancer
CN102653783B (zh) * 2011-03-02 2014-06-04 中国人民解放军第二军医大学东方肝胆外科医院 一种hvem基因在制备肝癌诊断和预后预测的产品中的应用
TWI700093B (zh) 2011-03-16 2020-08-01 法商賽諾菲公司 雙重ｖ區類抗體蛋白質之用途
EP2686688B1 (en) 2011-03-17 2019-05-08 Cernostics, Inc. Systems and compositions for diagnosing barrett's esophagus and methods of using the same
BR112013025198A2 (pt) 2011-03-31 2018-12-04 Alethia Biotherapeutics Inc. anticorpos contra antígeno 1 associado a rim e fragmentos de ligação a antígeno do mesmo
CN102735840B (zh) * 2011-04-13 2014-06-04 中国医学科学院肿瘤研究所 用于诊断或筛查卵巢癌的试剂
WO2012174569A2 (en) * 2011-06-17 2012-12-20 The Board Of Trustees Of The University Of Arkansas New markers for early diagnosis of ovarian cancer, monitoring during therapy, and new therapy options during and after chematherapy
TW201312117A (zh) * 2011-07-28 2013-03-16 Univ Pennsylvania 用以診斷與漿液相關之腫瘤細胞的症狀及特性的方法及試劑
EA034414B1 (ru) 2012-01-09 2020-02-05 Адс Терапьютикс Са Способ лечения тройного негативного рака молочной железы
JP6375947B2 (ja) * 2012-05-11 2018-08-22 味の素株式会社 取得方法、評価装置、評価方法、評価プログラム、評価システムおよび端末装置
CN102749448B (zh) * 2012-07-27 2014-07-02 复旦大学附属中山医院 用于评估肺腺癌化疗效果的试剂盒
US20140045196A1 (en) * 2012-08-13 2014-02-13 University Of Tokyo Methods of prognosis and diagnosis of cancer
GB201220573D0 (en) 2012-11-15 2013-01-02 Univ Central Lancashire Methods of diagnosing proliferative disorders
CA2893158A1 (en) * 2012-11-30 2014-06-05 Applied Proteomics, Inc. Method for evaluation of presence of or risk of colon tumors
EP3159695A3 (en) * 2013-06-20 2017-07-05 The Trustees of The University of Pennsylvania Methods for diagnosing pancreatic cancer
WO2015187158A1 (en) * 2014-06-04 2015-12-10 Indevr, Inc. Universal capture array for multiplexed subtype-specific quantification and stability determination of influenza proteins
US10662478B2 (en) * 2014-08-28 2020-05-26 Hackensack University Medical Center Serine proteases as biomarkers for ovarian cancer
WO2016042202A1 (en) 2014-09-17 2016-03-24 Wallac Oy Method for determining the risk of preterm birth
AU2014407088B2 (en) 2014-09-26 2021-09-23 Somalogic Operating Co., Inc. Cardiovascular risk event prediction and uses thereof
WO2016094409A1 (en) * 2014-12-09 2016-06-16 Villarreal Anna Methods and devices for female health monitoring
CN105807061B (zh) * 2014-12-29 2018-08-21 中国辐射防护研究院 电离辐射生物标记的筛选方法及由此确定的b8x1j0、upf1蛋白的用途
KR101765999B1 (ko) * 2015-01-21 2017-08-08 서울대학교산학협력단 암 바이오마커의 성능 평가 장치 및 방법
CN104655849B (zh) * 2015-02-15 2016-08-24 河北博海生物工程开发有限公司 一种肿瘤靶标的筛选方法
EP3073268A1 (en) * 2015-03-27 2016-09-28 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Biomarker panel for diagnosing cancer
CN104698192A (zh) * 2015-03-31 2015-06-10 首都医科大学 与结直肠癌显著相关的血清多肽生物标志物及其应用
CN104991065B (zh) * 2015-07-07 2017-01-11 复旦大学附属金山医院 一种用于诊断乳腺癌的三联标志物及其应用
JP7145503B2 (ja) * 2015-09-17 2022-10-03 ヒスタイド アクツィエンゲゼルシャフト 腫瘍細胞を非腫瘍細胞に変換するための医薬的連合体及びその使用
ITUB20155701A1 (it) * 2015-11-19 2017-05-19 Saverio Alberti Uso di Trop-2 circolante sierico come nuovo biomarcatore tumorale
RU2625018C2 (ru) * 2015-12-16 2017-07-11 Федеральное Государственное Бюджетное Учреждение Науки Институт Молекулярной Биологии Им. В.А. Энгельгардта Российской Академии Наук (Имб Ран) Способ диагностики/скрининга колоректального рака, основанный на одновременном количественном определении онкомаркеров белковой природы, антител к гликанам, иммуноглобулинов G, А и М в крови человека на биологическом микрочипе
JP2019515265A (ja) * 2016-04-20 2019-06-06 エーザイ インク． バイオマーカーを使用する漿液性卵巣がんの予後
US11205103B2 (en) 2016-12-09 2021-12-21 The Research Foundation for the State University Semisupervised autoencoder for sentiment analysis
CN106872593B (zh) * 2017-02-04 2021-05-04 江西省妇幼保健院 溶血磷脂酸作为标志物在检测子宫内膜异位症中的应用
CN114839374A (zh) 2017-03-28 2022-08-02 相达生物科技国际有限公司 用于在液体活检中准确诊断疾病靶向生物标记的方法
CN114632349A (zh) 2017-06-01 2022-06-17 相达生物科技美国有限公司 用于多孔材料中双水相分离的相分离行为改性剂
TWI650664B (zh) * 2017-08-21 2019-02-11 遺傳軌跡股份有限公司 建立蛋白質功能缺失評估模型的方法以及利用上述模型的風險評估方法與系統
WO2019046563A1 (en) 2017-09-01 2019-03-07 Phase Diagnostics, Inc. METHOD AND DEVICE FOR USING AQUEOUS BIPHASE SYSTEMS (ATPS) TO IMPROVE THE DIAGNOSIS OF SEXUALLY TRANSMITTED INFECTIONS
WO2019144030A1 (en) 2018-01-19 2019-07-25 Yin To Chiu Method for isolating and purifying nucleic acids using a solid-liquid phase system
US11332796B2 (en) 2018-01-19 2022-05-17 Phase Scientific International, Ltd. Composition and method for concentration and enrichment of nucleic acids
US11479765B2 (en) 2018-01-19 2022-10-25 Phase Scientific International, Ltd. Method of isolating exosomes using encapsulation and aqueous micellar system
WO2019238944A1 (en) * 2018-06-15 2019-12-19 Olink Proteomics Ab Biomarker panel for ovarian cancer
CN108957014A (zh) * 2018-09-27 2018-12-07 郑州大学第附属医院 结直肠癌血清标志物、表达评估方法、试剂盒及应用
IL301664A (en) * 2020-10-05 2023-05-01 Gina Life Diagnostics Ltd Identification and characterization of specific biomarkers for ovarian cancer in vaginal secretions
CN112986588B (zh) * 2021-04-21 2021-08-06 天津云检医疗器械有限公司 脂质标志物在制备结直肠癌检测试剂盒中的用途
CN113341156B (zh) * 2021-06-01 2022-02-22 中国医学科学院北京协和医院 鉴别卵巢子宫内膜异位症/卵巢癌的试剂及其应用
CN114574587B (zh) * 2022-04-06 2022-12-02 北京莱盟君泰国际医疗技术开发有限公司 一种用于结直肠癌检测的标记物组合物及其应用
CN117173083A (zh) * 2022-07-22 2023-12-05 浙江省肿瘤医院 基于舌象图像和肿瘤标志物的肿瘤预测系统、方法及应用

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2004A (en) * 1841-03-12 Improvement in the manner of constructing and propelling steam-vessels
US545900A (en) 1895-09-10 Island
US2003A (en) * 1841-03-12 Improvement in horizontal windivhlls
US545581A (en) 1895-09-03 david j
US2005A (en) * 1841-03-16 Improvement in the manner of constructing molds for casting butt-hinges
US5008185A (en) * 1985-11-04 1991-04-16 Cell Analysis Systems, Inc. Methods and apparatus for the quantitation of nuclear proteins
JP2721900B2 (ja) * 1988-09-18 1998-03-04 株式会社ニチレイ 癌診断薬及びそれを用いた腫瘍マーカーの回収方法
ATE220916T1 (de) * 1993-02-19 2002-08-15 Genentech Inc Ligand antagonisten zur behandlung von brustkrebs
US5583110A (en) 1994-02-08 1996-12-10 Altchek; Albert Detection of neoplasms by hormonal tumor stimulation test
US5792748A (en) 1995-06-07 1998-08-11 The General Hospital Corporation Method for inhibiting neoplastic disease in mammals
US5798266A (en) 1996-08-27 1998-08-25 K-Quay Enterprises, Llc Methods and kits for obtaining and assaying mammary fluid samples for breast diseases, including cancer
US6235474B1 (en) 1996-12-30 2001-05-22 The Johns Hopkins University Methods and kits for diagnosing and determination of the predisposition for diseases
AU5496798A (en) * 1997-01-20 1998-08-07 Shionogi & Co., Ltd. Human cc chemokine slc
WO1999064626A2 (en) 1998-06-06 1999-12-16 Genostic Pharma Limited Probes used for genetic profiling
US6610484B1 (en) * 1999-01-26 2003-08-26 Cytyc Health Corporation Identifying material from a breast duct
US6335170B1 (en) * 1999-02-22 2002-01-01 Torben F. Orntoft Gene expression in bladder tumors
EP1159619A2 (en) 1999-03-15 2001-12-05 EOS Biotechnology, Inc. Methods of diagnosing and treating breast cancer
US6642009B2 (en) * 1999-05-17 2003-11-04 Cytyc Health Corporation Isolated ductal fluid sample
ATA162699A (de) * 1999-09-23 2002-08-15 Vitateq Biotechnology Gmbh Verfahren zur fertilitätsbestimmung von säugetieren, insbesondere von menschen
WO2001040271A2 (en) 1999-12-01 2001-06-07 Ludwig Institute For Cancer Research Cancer associated antigens and uses therefor
US6448086B1 (en) * 2000-01-18 2002-09-10 Diagnostic Systems Laboratories, Inc. Insulin-like growth factor system and cancer
WO2001054713A1 (en) 2000-01-28 2001-08-02 Musc Foundation For Research Development Methods for determining risk of developing cervical cancer
CA2404088A1 (en) * 2000-03-23 2001-09-27 Greenville Hospital System Bi-functional cancer treatment agents
GB0023080D0 (en) 2000-09-20 2000-11-01 Univ Liverpool Prognostic indicator
JP4050612B2 (ja) * 2000-11-13 2008-02-20 アトッサ ヘルスケア，インコーポレイティド 患者の乳房器官から生体サンプルを採集するためのサンプル採集装置
AU2002230997A1 (en) * 2000-12-15 2002-06-24 Genetics Institute, Llc Methods and compositions for diagnosing and treating rheumatoid arthritis
US20040029114A1 (en) * 2001-01-24 2004-02-12 Eos Technology, Inc. Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
WO2002062852A1 (fr) * 2001-02-05 2002-08-15 Chugai Seiyaku Kabushiki Kaisha Proteine receptrice exprimee sur des cellules
EP1256354A1 (en) * 2001-05-11 2002-11-13 Schering Corporation Methods for treating cancer
US7026121B1 (en) * 2001-06-08 2006-04-11 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
US6905827B2 (en) * 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
US7235358B2 (en) * 2001-06-08 2007-06-26 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
US20030044862A1 (en) * 2001-06-22 2003-03-06 The Board Of Trustees Of The Leland Stanford Jr. University Diagnostic marker for tumor hypoxia and prognosis
ATE330279T1 (de) 2001-07-06 2006-07-15 Koninkl Philips Electronics Nv Verfahren und gerät zur verarbeitung einer mediendatei
WO2003022987A2 (en) * 2001-07-26 2003-03-20 Eos Biotechnology, Inc. Methods of diagnosis of hepatitis c infection, compositions and methods of screening for modulators of hepatitis c infection
US20050106624A1 (en) * 2001-09-25 2005-05-19 Kazuki Sasaki Search for cancer markers by a novel screening method
WO2003030725A2 (en) 2001-10-11 2003-04-17 The Johns Hopkins University Pancreatic cancer diagnosis and therapies
ES2337989T3 (es) 2001-12-18 2010-05-03 Endocube Sas Nuevas proteinas asociadas a la muerte de la familia thap y rutas par4 relacionadas implicadas en el control de la apoptosis.
JP2004033210A (ja) * 2002-02-20 2004-02-05 Ncc Technology Ventures Pte Ltd 癌診断に関する物および方法
WO2003076942A2 (fr) * 2002-03-13 2003-09-18 Biomerieux Quantification de cellules tumorales circulantes issues de cancers solides
US20030232398A1 (en) 2002-03-28 2003-12-18 Macmurray James P. Use of ROC plots of genetic risk factor to predict risk of sporadic breast cancer
JP4511108B2 (ja) 2002-05-31 2010-07-28 オンコリクス インコーポレイテッド ヒトプロラクチン拮抗剤−血管新生阻害剤融合蛋白質
ATE261126T1 (de) 2002-08-01 2004-03-15 Mtm Lab Ag Verfahren für lösung-basierte diagnose
WO2004013609A2 (en) * 2002-08-06 2004-02-12 The Johns Hopkins University Use of biomarkers for detecting ovarian cancer
CA2504443A1 (en) * 2002-10-30 2004-05-13 Pointilliste, Inc. Methods for producing polypeptide-tagged collections and capture systems containing the tagged polypeptides
US8163896B1 (en) * 2002-11-14 2012-04-24 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
CA2535805A1 (en) * 2003-08-15 2005-02-24 University Of Pittsburgh Of The Commnonwealth System Of Higher Education Multifactorial assay for cancer detection
EP2336779B1 (en) 2004-02-19 2013-07-31 Yale University Kit for the identification of ovarian cancer protein biomarkers using proteomic techniques

Also Published As

Publication number Publication date
US9470688B2 (en) 2016-10-18
US20150233929A1 (en) 2015-08-20
EP2026071A2 (en) 2009-02-18
AU2005217375C1 (en) 2012-06-07
EP2026071B1 (en) 2013-07-31
AU2005217375A1 (en) 2005-09-09
EP2336779B1 (en) 2013-07-31
AU2005217375B2 (en) 2011-05-19
CA2557438A1 (en) 2005-09-09
JP2007523346A (ja) 2007-08-16
US20170138950A1 (en) 2017-05-18
IL177591A0 (en) 2006-12-10
HK1129729A1 (en) 2009-12-04
EP2336779A1 (en) 2011-06-22
US20050214826A1 (en) 2005-09-29
CN1922490A (zh) 2007-02-28
US7666583B2 (en) 2010-02-23
EP1723428A2 (en) 2006-11-22
US8975379B2 (en) 2015-03-10
US20100311047A1 (en) 2010-12-09
JP2010281836A (ja) 2010-12-16
JP4912894B2 (ja) 2012-04-11
IL177591A (en) 2011-12-29
CA2557438C (en) 2017-01-17
JP2010281835A (ja) 2010-12-16
US20160018402A2 (en) 2016-01-21
CN1922490B (zh) 2012-07-04
US10168334B2 (en) 2019-01-01
WO2005083440A3 (en) 2006-03-16
EP2026071A3 (en) 2009-09-02
WO2005083440A2 (en) 2005-09-09

Similar Documents

Publication Publication Date Title
HK1159249A1 (en) Kit for the identification of ovarian cancer protein biomarkers using proteomic techniques
ATE289685T1 (de) Verfahren zum nachweis von karzinomen in solubilisierten zervikalen körperproben
WO2005042761A3 (en) Biomarkers for amyotrophic lateral sclerosis
WO2004112589A3 (en) Method for the detection of gene transcripts in blood and uses thereof
WO2007051069A3 (en) Urinary proteomic biomarker patterns in preeclampsia
WO2007030949A3 (en) Methods of diagnosing ovarian cancer and kits therefor
WO2005098445A3 (en) Lung cancer biomarkers
WO2005103719A3 (en) Using plasma proteomic pattern for diagnosis, classification, prediction of response to therapy and clinical behavior, stratification of therapy, and monitoring disease in hematologic malignancies
WO2007109881A8 (en) Biomarkers useful for diagnosing prostate cancer, and methods thereof
PL2341344T3 (pl) Sposób diagnozowania wielotorbielowatości nerek
DK1200832T3 (da) Annexiner og autoantistoffer anvendt som markörer for lungecancer og ösofageal cancer
EP1700096A4 (en) PROOF OF PROTEINS AND PRIONS WITH CHANGED CONFORMATION
DE602006006855D1 (de) Morbus alzheimer-spezifische veränderungen des erkheimer-spezifische molekulare biomarker (adsmb)
WO2005081908A3 (en) Reagents, kits and methods for immunodetection of epitopes on molecules
WO2005071407A3 (en) Methods of diagnosing acute coronary syndrome by measuring urotensin ii
DK1535076T3 (da) Polypeptid-biomarkörer til diagnose af Alzheimers sygdom
WO2006002240A8 (en) Computer systems and methods for constructing biological classifiers and uses thereof
WO2006085121A3 (en) Vgp peptide fragments as biomarkers for schizophrenic and bipolar disorders
GB201222576D0 (en) Method for diagnosing lung cancer
WO2005034727A3 (en) Method for diagnosing head and neck squamous cell carcinoma
WO2007033367A3 (en) Salivary protein and rna for breast cancer detection
ATE479778T1 (de) Verfahren zur diagnose nicht-kleinzelliger lungenkarzinome über die trna-dihydrouridin- synthaseaktivität von urlc8
WO2007075672A3 (en) Prognostic cancer markers
ATE503186T1 (de) Verwendung neuartiger biomarker zum nachweis von hodenkrebs in situ und abgeleiteten krebserkrankungen in menschlichen proben
WO2004083449A3 (en) Detection of urinary mesothelin-/megakaryocyte potentiating factor-related peptides for assessment of ovarian cancer

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20170118